Eyenuk

What Eyenuk does

Eyenuk is a Woodland Hills, California-based medtech company founded in 2010 that develops AI-powered autonomous eye screening technology, with its core EyeArt AI Eye Screening System being the first FDA-cleared AI for autonomous detection of both more-than-mild and vision-threatening diabetic retinopathy. The platform uses deep learning neural networks and image analysis algorithms to assess retinal fundus image quality, detect lesions, and grade disease severity against internationally recognized clinical scales (ICDR, NHS NDESP), returning screening reports in under 60 seconds without requiring eye dilation or expert human grading. EyeArt is compatible with multiple FDA-cleared fundus cameras from manufacturers including Topcon, Zeiss, Centervue, Remidio, CSO, and Next Sight, and the company also offers EyeScreen, a Human+AI diagnostic service combining AI detection with specialist adjudication for ICD-10 compliant reporting.

The product portfolio spans the cleared EyeArt and EyeScreen services, compatible retinal camera hardware, and a pipeline that includes EyeMark (DR progression tracking), EyeArt extensions for AMD and glaucoma detection, and EyeRead UWF (ultra-widefield lesion analysis). Regulatory positioning is unusually deep: FDA 510(k) clearance (2020, expanded 2023 with multi-camera and Real-Time Image Quality Feedback), EU MDR Class IIb CE marking (first EU MDR certification for autonomous AI DR/AMD/glaucoma in Jan 2023), Health Canada Medical Device License, ISO 13485 MDSAP registration, HIPAA compliance audited by A-Lign, and CMS reimbursement under CPT code 92229. The AI Predictive Biomarkers platform extends the underlying technology toward risk assessment for stroke, cardiovascular disease, and Alzheimer's.

Eyenuk operates a sales-led, enterprise-focused go-to-market targeting primary care physicians, endocrinologists, ophthalmologists/optometrists, nurses, health plans/payers, and national health systems across 18+ countries including the US, UK, Norway, Germany, Italy, India, Canada, South Africa, Armenia, and Vietnam. Named customers include the Los Angeles County Department of Health Services (800K+ patients), Norway South-Eastern Regional Health Authority, UK NHS, Discovery Health, Armenian EyeCare Project, Diabetes Center Mergentheim, and the University Eye Clinic of Genoa. Revenue derives from subscription/per-screen licensing of the EyeArt system and per-report fees for the EyeScreen service. The company has raised over $43 million in total funding, including a $26 million Series A in October 2022 led by AXA IM Alts, and in January 2025 appointed Mads Dall as Chairman and Gaurav Agarwal as CEO.

Name

Eyenuk

Legal name

Eyenuk, Inc.

Website

https://eyenuk.com

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

11–50 employees

Short description

Eyenuk is a medtech company developing AI-powered autonomous eye screening, led by its FDA-cleared EyeArt system for diabetic retinopathy detection. The platform serves primary care physicians, endocrinologists, ophthalmologists, health plans, and national health systems across 18+ countries.

Ownership category

akta.pro rank

Product category

AI Medical Imaging Software

NAICS

Ophthalmic Goods Manufacturing (339115)

SIC

Ophthalmic Goods (3851)

akta.pro primary industry

Ocular Imaging & Diagnostic Testing Centers (HLAKAKAN)

akta.pro secondary industries

Vision & Ophthalmic Diagnostic Centers (Optometry/OCT/Retinal Imaging) (HLAFAKAI), Visual Field & Functional Vision Testing (Perimetry, ERG/VEP, Contrast Sensitivity) (HLAHAJAC)

Keywords

• AI eye screening
• Diabetic retinopathy detection
• Retinal image analysis
• Medical imaging AI
• Autonomous diagnostics

Headquarters

HQ city

Los Angeles

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

1. EyeArt AI Screening System: Revenue from licensing and deploying the EyeArt AI Eye Screening System to healthcare providers including hospitals, clinics, and health systems. The system is sold as a cloud-based software service with per-screen or subscription pricing.
2. EyeScreen Human+AI Diagnostic Service: Diagnostic service revenue combining AI screening with human expert grading, providing ICD-10 compliant reports and reimbursable under existing CPT codes.
3. Regulatory Compliance Services: Supporting healthcare providers with compliance, HEDIS measure improvement, and CMS Five-Star Quality Ratings through diabetic retinopathy screening programs.

Go-to-market motion2 records

Distribution channels5 records

Marketing channels7 records

Core offering

Eyenuk develops and commercializes the EyeArt AI Eye Screening System, an FDA-cleared, cloud-based software that autonomously analyzes retinal fundus images to detect diabetic retinopathy (and under EU MDR, age-related macular degeneration and glaucoma) without requiring eye dilation or expert human grading. The company also operates the EyeScreen Human+AI Diagnostic Service, which combines the AI with specialist human grading and produces ICD-10 compliant reports.

Product overview

Eyenuk offers a portfolio of AI-powered eye screening products centered on the EyeArt system, which provides autonomous AI detection of diabetic retinopathy and other eye diseases. The core offering includes the EyeArt AI Eye Screening System (FDA-cleared, CE-marked, Health Canada licensed) for primary care and diabetes clinic deployment, complemented by the EyeScreen Human+AI Diagnostic Service that combines AI detection with human expert grading. The company also supplies compatible retinal cameras and maintains a pipeline of products including EyeMark for retinopathy progression tracking and EyeArt extensions for AMD and glaucoma detection. All products leverage deep learning-based computer vision to analyze retinal fundus images, with results returned in under 60 seconds.

Differentiator

Problem solved

Functional benefit

Brands

• EyeArt: AI Eye Screening System for autonomous detection of diabetic retinopathy, age-related macular degeneration, and glaucoma
• EyeScreen
• EyeMark
• EyeRead

Products and services

• EyeArt AI Eye Screening System Cloud-based AI software that autonomously analyzes retinal fundus images to detect diabetic retinopathy (and AMD/glaucoma under EU MDR), returning screening reports in under 60 seconds without eye dilation or expert human grading. Sold to primary care clinics, endocrinology/diabetes centers, ophthalmology practices, health systems, and health plans.
• EyeScreen Human+AI Diagnostic Service Diagnostic service that pairs the EyeArt AI with independent human expert graders (and expert adjudication on disagreement) to identify referable diabetic retinopathy, producing ICD-10 compliant reports for healthcare providers.

Quantifiable outcome

• 96% sensitivity, 88% specificity for detecting more-than-mild DR; 97% sensitivity, 90% specificity for vision-threatening DR in pivotal clinical trial
• +5 more outcomes

Named customers11 records

Segments6 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature5 records

Partnerships

Ten partnerships are on record, tiered core, flagship, minor and major.

• South-Eastern Norway Regional Health AuthoritycoreStrategic or Co-development Partner · 17 September 2025First national health system deployment of EyeArt autonomous AI eye screening technology for diabetic retinopathy screening across Norway. Eyenuk's technology chosen as part of Norway's National Health System for nationwide DR screening.
• Vision Loss Rehabilitation CanadaflagshipStrategic or Co-development Partner · 16 August 2022Bringing AI-driven diabetic eye screening to rural and Indigenous communities in Northern and Eastern Ontario, Canada, improving access to vision-saving screening in remote areas.
• Population Health AllianceminorStrategic or Co-development Partner · 10 March 2022Eyenuk joined the Population Health Alliance to promote autonomous AI technology for improving diabetes complications management at point-of-care and community settings.
• Discovery Health (South Africa)flagshipStrategic or Co-development Partner · 7 December 2021Discovery Health launched EyeArt AI system as a diabetic retinopathy screening benefit for members, making vision-saving screening accessible in South Africa through the Discovery health platform.
• HealthCare Dynamics International (HCDI)majorChannel Partner/ Reseller/ Distributor · 28 July 2021HCDI, a minority woman-owned healthcare quality improvement company, adopted EyeArt AI technology to help health plans close HEDIS gaps and improve quality measures.
• Fred Hollows FoundationflagshipStrategic or Co-development Partner · 26 July 2021Fred Hollows Foundation supported diabetic eye testing program in Vietnam using Eyenuk's AI technology, extending eye screening to underserved populations.
• Devlyn Optical / Grupo DevlynmajorChannel Partner/ Reseller/ Distributor · 8 June 2020Multinational optical retailer piloting AI and telemedicine technology using EyeArt for diabetic retinopathy screening at retail optical locations across Latin America.
• World Diabetes FoundationflagshipStrategic or Co-development Partner · 14 November 2019World Diabetes Foundation supported the Armenian EyeCare Project's nationwide DR screening program using EyeArt technology, with approximately $1.5M+ in funding to bring screening to 87 clinics across Armenia.
• Armenian EyeCare ProjectflagshipStrategic or Co-development PartnerNonprofit implementing nationwide AI eye screening program in Armenia using EyeArt technology, screening over 10,000 patients with support from World Diabetes Foundation and Ministry of Health of Armenia.
• Retinal Camera Manufacturers (Topcon, Zeiss, Centervue, Remidio, CSO, Next Sight)coreTechnology or IntegrationIntegration partnerships with multiple retinal camera manufacturers enabling EyeArt AI analysis to work with various fundus camera systems, providing flexibility for healthcare providers.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• AEYE Health: AEYE Health is an AI medical device company developing autonomous DR screening algorithms that compete directly with EyeArt for FDA-cleared, primary-care-deployable diabetic retinopathy detection.
• Digital Diagnostics: Digital Diagnostics (formerly IDx) developed IDx-DR, the first FDA-cleared autonomous AI diagnostic system for diabetic retinopathy, making it the most direct head-to-head competitor to Eyenuk's EyeArt in US primary care and health system channels.
• iHealthScreen: iHealthScreen provides AI-based automated screening for diabetic retinopathy and age-related macular degeneration using retinal image analysis, directly competing with EyeArt in the autonomous AI DR screening category.
• RetinAI Medical: RetinAI Medical (Ikerian) develops AI platforms for ophthalmic image analysis and disease management, including DR and AMD, with similar deep-learning retinal analysis capabilities to Eyenuk's EyeArt.

Emerging players

• MediWhale: MediWhale is an emerging AI health company applying deep learning to retinal fundus images to predict systemic disease risk (cardiovascular, kidney), overlapping with Eyenuk's stated AI Predictive Biomarkers roadmap.
• Thirona: Thirona develops AI-based medical image analysis software including retinal image analysis tools, with comparable computer-vision approach to EyeArt though focused across multiple imaging modalities.
• Aidoc: Aidoc is a clinical AI company deploying deep learning image analysis in healthcare workflows; while focused on radiology rather than ophthalmology, it represents an adjacent peer in regulated clinical-AI deployment and enterprise hospital sales.

Broad incumbents

• Topcon Healthcare: Topcon is a major ophthalmic device manufacturer producing fundus cameras and screening solutions that Eyenuk integrates with; it is both a partner and a potential competitor as it expands AI capabilities into its hardware.
• Carl Zeiss Meditec: Carl Zeiss Meditec is a leading ophthalmic devices and diagnostics company whose fundus cameras integrate with EyeArt; it is a strategic integration partner and a broader incumbent capable of embedding competing AI into its installed base.
• Google Health: Google Health has published and deployed AI models for diabetic retinopathy screening (e.g., in India with Aravind Eye Hospital); its research and product efforts represent a large-scale potential competitor to Eyenuk's autonomous AI DR screening.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/EyenukInc
• YouTubeyoutube.com/channel/UClpK-To5-z5cQIFpSbACprA
• Facebookfacebook.com/eyenuk
• LinkedInlinkedin.com/company/eyenuk-llc

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds13 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Eyenuk